Study on Combination Treatment with 177Lu Girentuximab, Cabozantinib, and Nivolumab for Patients with Advanced Clear Cell Kidney Cancer

Inclusion Criteria

• Must be able to understand and sign a consent form before any study procedures.
• Must be 18 years or older.
• Must have advanced or metastatic kidney cancer with clear cell type.
• Must have at least one tumor that can be measured by scans.
• Must be in good general health with an ECOG performance status of 0 or 1.
• Must have adequate organ function, including specific blood counts and kidney and liver function.
• Women of childbearing potential must have a negative pregnancy test before starting treatment.
• Must agree to use effective birth control during the study and for 120 days after the last dose.
• Must be able to swallow pills.
• Must provide a tumor tissue sample.
• Patients with brain metastases can participate if the brain tumors are stable and not life-threatening.

Exclusion Criteria

• Have received any prior treatment for metastatic kidney cancer.
• Have a history of certain brain or spinal cord conditions.
• Have an autoimmune disease requiring treatment.
• Have uncontrolled high blood pressure.
• Have had major heart problems in the last 6 months.
• Have any other serious medical or psychiatric conditions that could interfere with the study.
• Have an active infection needing treatment.
• Are participating in another clinical trial.
• Are taking certain medications that affect the liver.
• Have digestive issues that could affect medication absorption.
• Have tumors affecting major blood vessels.
• Have had major surgery recently without full recovery.
• Have another active cancer, except for certain skin cancers or cervical cancer in situ.